Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

BSH 2018 | The TAMARIN study: tamoxifen for MPNs

Claire Harrison • 16 Apr 2018

BSH 2018

Myeloproliferative Neoplasms Tamoxifen

TAMARIN

An upcoming study is investigating a new therapeutic strategy for the treatment of myeloproliferative neoplasms (MPNs). In this interview, Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK, gives an overview of the TAMARIN study (ISRCTN65011803); a study supported by Bloodwise’s Trials Acceleration Programme (TAP), investigating the effects of the anti-estrogen therapy tamoxifen on JAK/CALR mutant allele burden and disease course in patients with MPNs. Prof. Harrison highlights the rationale and design of this upcoming study. This video was recorded at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting in Liverpool, UK.

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more

Claire Harrison et al. • 11 Dec 2023

The value of novel JAK2 and CALR-targeted therapies in MPNs

Claire Harrison • 24 Apr 2023

The role of transplantation in MPNs & factors to consider when selecting patients for transplant

Claire Harrison • 24 Apr 2023

Optimizing current treatment approaches in myelofibrosis

Claire Harrison • 24 Apr 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023